+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of a novel des-fluoro quinolone BMS-284756 against rapidly growing mycobacteria and Nocardia isolates



In vitro activity of a novel des-fluoro quinolone BMS-284756 against rapidly growing mycobacteria and Nocardia isolates



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 175



Background: BMS-284756 is a novel des-F(6) quinolone with potent activity against Gram-positive bacteria. In this study, we determined the activity of BMS-284756 (BMS), clarithromycin (CLR), doxycycline (DOX), linezolid (LNZ), imipenem (IPM), amikacin (AMK), and trimethoprim-sulfamethoxazole (SXT) against rapidly growing mycobacteria and Nocardia isolates. Method: MICs were determined by the microbroth method using cation-supplemented Mueller-Hinton broth (plus 0.2 U/ml thymidine phosphorylase for SXT), inocula of apprxeq105 CFU/ml, and incubation at 30degreeC (35degreeC for Nocardia) for 5 days (except for M. fortuitum, for 3 days) (NCCLS M24-T2). Results: The MIC50 (or median MIC, when <10 strains tested) in mug/ml are given. Conclusions: BMS is active against many rapidly growing mycobacterial and Nocardia strains, and may prove to be useful in the treatment of infections caused by these intracellular pathogens.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035104746

Download citation: RISBibTeXText


Related references

In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. Journal of Antimicrobial ChemoTherapy 50(1): 140-142, 2002

Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 49(2): 283-287, 2002

In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. Journal of Antimicrobial ChemoTherapy 49(4): 698-701, 2002

In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest. Journal of Clinical Microbiology 54(6): 1586-1592, 2017

In vitro activity of the novel des- fluoro quinolone, BMS-284756, against anaerobic bacteria. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 173, 2000

Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagnostic Microbiology and Infectious Disease 44(2): 187-194, 2002

The in vitro activity of the novel des- fluoro quinolone BMS-284756 against fastidious bacterial species. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 174, 2000

In vitro activity of linezolid against isolates of rapidly growing mycobacteria. Abstracts of the General Meeting of the American Society for Microbiology 100: 654, 2000

Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Veterinary Microbiology 153(3-4): 240-245, 2012

The in vitro activity of the novel des- fluoro quinolone BMS-284756 against anaerobes, mycoplasma, ureaplasma, chlamydia, and mycobacterium spp. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 174, 2000

In vitro activity of novel Des-F quinolone, BMS-284756, against 590 anaerobic clinical isolates. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 173, 2000

Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Antimicrobial Agents and ChemoTherapy 46(4): 1119-1121, 2002

The in vitro activity of the novel des- fluoro quinolone BMS-284756 against gram-positive and gram-negative aerobic bacteria. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 174, 2000

Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin pradofloxacin. 2011

Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Antimicrobial Agents and ChemoTherapy 40(4): 874-878, 1996